Skip to main content
. 2022 Apr 5;8:163. doi: 10.1038/s41420-022-00960-3

Fig. 5. Recombinant sST2 disrupts the protection of IL-37D against obesity, insulin resistance, and hepatic steatosis in HFD-fed mice.

Fig. 5

IL-37Dtg and WT mice were fed on HFD for 19 weeks (n = 5 per group), recombinant sST2 was intraperitoneally injected into IL-37Dtg mice during the last 3 weeks (2 μg every 3 days). Body weight was recorded during (a) and after (b) the intervention. Glucose tolerance test (GTT, c) and insulin tolerance test (ITT, e) were performed, respectively, the values of area under the curve in GTT (d) and ITT (f) were measured. The fasting level of blood glucose was measured (g). The weight of inguinal WAT (h) was examined and the secretion levels of IL-4 (i), IL-5 (j), IL-13 (k) from its explants were detected by ELISA. Data represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 determined by two-way ANOVA (a, c, e) or one-way ANOVA (b, d, f–k).